SURPASS-CVOT trial results

Inclusion Criteria: * Men or women at least 40 years old with a diagnosis of type 2 diabetes * Established cardiovascular disease, including at least 1 of the following: * Coronary artery disease (CAD) with any of the following: * Documented history of spontaneous myocardial infarction (MI) * ≥50% stenosis in 1 or more major coronary arteries, determined by invasive angiography * ≥50% stenosis in 2 or more major coronary arteries, determined by computed tomography coronary angiography (CTCA) * History of surgical or percutaneous coronary revascularization procedure * Cerebrovascular disease - any of the following: * Documented history of ischemic stroke * Carotid arterial disease with ≥50% stenosis, documented by carotid ultrasound, magnetic resonance imaging (MRI), or angiography * Carotid stenting or surgical revascularization * Peripheral arterial disease with either of the following: * Intermittent claudication and ankle-brachial index \<0.9 * Prior nontraumatic amputation or peripheral vascular procedure (eg, stenting or surgical revascularization), due to peripheral arterial ischemia * Note: Supporting medical documentation is required in all instances * HbA1c ≥7% (≥53 mmol/mol) and ≤10.5% (≤91.3 mmol/mol) based on central laboratory assessment at screening * Body mass index (BMI) ≥25 kg/m2 * At the time of signing the informed consent: Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical trials. * Male patients: Men, regardless of their fertility status, with nonpregnant women of childbearing potential (WOCBP) partners must agree to either remain abstinent (if this is their preferred and usual lifestyle) or use condoms, as well as 1 additional highly effective (less than 1% failure rate) method of contraception (such as combination oral contraceptives, implanted contraceptives, or intrauterine devices) or effective method of contraception (such as diaphragms with spermicide or cervical sponges) for the duration of the study and until their plasma concentrations are below the level that could result in a relevant potential exposure to a possible fetus, predicted to be 90 days following the last dose of study drug. * Men and their partners may choose to use a double-barrier method of contraception. (Barrier protection methods without concomitant use of a spermicide are not an effective or acceptable method of contraception. Thus, each barrier method must include use of a spermicide. It should be noted, however, that the use of male and female condoms as a double barrier method is not considered acceptable due to the high failure rate when these barrier methods are combined). * Periodic abstinence (eg, calendar, ovulation, symptothermal, or postovulation methods), declaration of abstinence just for the duration of a trial, and withdrawal are not acceptable methods of contraception....